^
    Back
    Association details:
    Biomarker:FGFR3 fusion
    Cancer:Urothelial Cancer
    Drug:Pemazyre (pemigatinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

    Excerpt:
    ...ORR in Participants With FGFR3 Mutations or Fusions on an ID Regimen`ORR in Participants With All Other FGF/FGFR Alterations`ORR in All Participants on an ID or CD Regimen in Combined Cohorts`Number of Participants With Any Treatment-emergent Adverse Event (TEAE)`Progression-free Survival (PFS)`Duration of Response (DOR)`Overall Survival...
    Trial ID:
    NCT02872714
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    Pemigatinib for Metastatic or Surgically Unresectable Urothelial Carcinoma With FGF/FGFR Genomic Alterations: Final Results From FIGHT-201

    Published date:
    11/14/2023
    Excerpt:
    Pemigatinib was generally well tolerated and demonstrated clinical activity in previously treated, unresectable or metastatic UC with FGFR3 mutations or fusions/rearrangements.
    DOI:
    10.1016/j.annonc.2023.10.794
    Trial ID:
    NCT02872714